Arcus Biosciences Announces Anti-TIGIT Program Update
Company Announcements

Arcus Biosciences Announces Anti-TIGIT Program Update

Arcus Biosciences Inc (RCUS) has released an update.

The Company released a press statement on January 29, 2024, providing updates on its anti-TIGIT clinical development program.

For further insights into RCUS stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TheFlyArcus Biosciences announces results from Part 1 of ARC-10 trial
TheFlyArcus Biosciences price target raised to $29 from $25 at Barclays
TipRanks Auto-Generated NewsdeskArcus Biosciences Reports Promising Trial Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App